FDA Panel Votes to Keep Bayer Drug on the Market
A Food and Drug Administration panel of outside medical experts said a Bayer AG drug, used to control bleeding in patients undergoing heart-bypass surgery, should stay on the U.S. market.
You may also like
Radial Artery Grafts Set To Improve Long Term Survival
The use of the radial artery in coronary artery bypass graft (CABG) procedures is likely to improve long-term graft survival if early […]
2 min read
Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease
Despite ACE2 serving as the portal for infection, the role of ACE inhibitors or angiotensin receptor blockers requires further investigation. COVID-19 poses a challenge for heart transplantation, impacting donor selection, immunosuppression, and post-transplant management.
1 min read